Point unveils new Indy site to shore up supply chain in fight against prostate cancer
With a new manufacturing facility and a candidate for prostate cancer in clinical trials, Point Biopharma is moving fast to bring its radioligand operations online. Now, it will get some help from the US Department of Energy.
Point will receive actinium-225 from the DOE’s Isotope Program to support its early-stage pipeline and in-house manufacturing of lutetium-177, a radioactive medicine that binds itself to tumor cells. The help will allow Point to stay on track to launch in 2023 and will supplement the company’s supply chain from TerraPower, NorthStar Medical and Ionetix. All of these partnerships will help bolster the company’s internal production, the company said.
To read Endpoints News become a free subscriber
Unlock this article instantly, along with access to limited free monthly articles and our suite of newsletters